Skip to main content
SpringerLink
Log in

Idiopathische Lungenfibrose

Tyrosinkinase-Inhibitor bremst Progression

  • infopharm
  • Published:
Pneumo News Aims and scope

Bei idiopathischer Lungenfibrose (IPF) bremst eine Behandlung mit dem antifibrotisch wirksamen Tyrosinkinasen-Inhibitor Nintedanib den Abfall der forcierten Vitalkapazität und verzögert damit die Progression der Erkrankung.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Quellen

  1. American Thoracic Society, International Conference, San Diego, 16.-21. Mai 2014

  2. Richeldi L et al. Efficacy and Safety of Nintedanib in Idiopathic Pulmonary Fibrosis. N Engl J Med 2014; DOI: 10.1056/NEJMoa1402584

  3. Global Media Evening “INPULSIS: A pivotal moment for IPF”, San Diego, 18.05.2014 (Veranstalter: Boehringer Ingelheim)

Download references

Author information

Authors and Affiliations

  1. http://www.springermedizin.de

    Dirk Einecke

Authors
  1. Dirk Einecke
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Einecke, D. Tyrosinkinase-Inhibitor bremst Progression. Pneumo News 7, 60 (2015). https://doi.org/10.1007/s15033-015-0085-z

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s15033-015-0085-z

Search

Navigation